Sucampo Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.17%34.570.9%$1199.89m
JNJJohnson & Johnson 1.59%143.210.7%$1130.41m
BMYBristol-Myers Squibb Co. 1.96%60.301.0%$996.19m
MRKMerck & Co., Inc. 1.11%79.660.7%$858.66m
ABBVAbbVie, Inc. 0.41%99.281.9%$814.41m
LLYEli Lilly & Co. 1.60%166.491.1%$710.26m
AZNAstraZeneca Plc 0.55%54.101.2%$302.78m
RPRXRoyalty Pharma Plc 0.11%45.780.1%$252.95m
VXRTVaxart, Inc. -15.74%6.210.0%$189.20m
NVSNovartis AG 1.11%88.540.2%$162.17m
GSKGlaxoSmithKline Plc -0.47%41.030.2%$121.97m
RGENRepligen Corp. -0.88%125.547.2%$119.09m
NVONovo Nordisk A/S -0.67%65.920.1%$94.20m
RETAReata Pharmaceuticals, Inc. 1.47%160.173.4%$89.00m
SNYSanofi 1.07%52.170.2%$80.97m

Company Profile

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.